GRAIL, Inc.

NASDAQ:GRAL

Medical - Diagnostics & Research

Healthcare
$102.10 +3.20%

+$1.90 today

Market cap
$4.59B
Beta
3.16
P/E (TTM)
-6.3
EPS (TTM)
-$9.73
52W Low $29.95High $118.84

Volume 0.62M

Average 0.77M

GRAL Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

GRAIL, Inc.NASDAQ: GRAL

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses growth accelerates

Q2 FY2026 other income / expenses of $7.08M rose 18.0% year over year, ahead of the -13.0% change in trailing-twelve-month other income / expenses. Sequentially, it fell 14.2% from the prior quarter.

Context

  • Other income / expenses amounted to 0.2% of revenue in FY2025, down 21.1 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.0% holds above the trailing-twelve-month pace of -13.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$7.08M-14.2% QoQ
Last fiscal yearDec 2025
-$341K-101.3% YoY
LTMJun 2026
$29.78M-13.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.0%——
1 year-101.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(341K) USD
Year-over-year change
-101.3%

Other Income / Expenses vs competitors

How GRAL compares with its peers on the latest reported figures

  • GRAL's LTM Jun 2026 other income / expenses of $29.78M is the 2nd highest of the 10 companies compared; the peer median is $11.62M.
  • Its year-over-year change of -13.0% is the 6th highest of 10, against a peer median of -8.1%.
  • Other income / expenses amounts to 18.0% of revenue for GRAL, versus a peer median of 2.0%.
GRAL Competitors Peer median
Other Income / Expenses for GRAL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$36.97M -8.1%—1.4%
GRALGRAIL, Inc.LTM Jun 2026$29.78M -13.0%—18.0%
FLGTFulgent Genetics, Inc.LTM Mar 2026$23.01M +2.7%+56.5%7.2%
GHGuardant Health, Inc.LTM Sep 2026$18.14M -59.5%—1.4%
CSTLCastle Biosciences, Inc.LTM Mar 2026$15.63M +35.1%+49.9%4.6%
NEONeoGenomics, Inc.LTM Jun 2026$11.62M +21.0%—1.5%
PSNLPersonalis, Inc.LTM Mar 2026$7M +141.3%+44.5%10.9%
BLLNBillionToOne, Inc.LTM Jun 2026-$5.4M -144.3%—1.4%
MYGNMyriad Genetics, Inc.LTM Mar 2026-$16.3M -579.2%—2.0%
WGSGeneDx Holdings Corp.LTM Jun 2026-$45.69M -1071.7%—10.1%
Peer median (excluding GRAL) $11.62M-8.1%+49.9%2.0%

Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.61M55.55M93.11M125.6M147.17M
Cost of Revenue114.62M172M188.72M203.62M209.75M
Gross Profit(100M)(116.45M)(95.61M)(78.02M)(62.57M)
Gross Margin-684.4%-209.6%-102.7%-62.1%-42.5%
Research & Development460.21M329.58M338.75M322.38M195.79M
Selling, General & Admin234.06M296.44M362.56M367.82M275.8M
Operating Expenses1.17B5.33B1.42B2.11B471.59M
Depreciation & Amortization58.45M154.76M158.7M158.06M156.34M
EBITDA(1.21B)(587.7M)(638.22M)(610.17M)(378.16M)
EBITDA Margin-8259.0%-1058.0%-685.5%-485.8%-257.0%
Operating Income(1.27B)(5.44B)(1.52B)(2.19B)(534.16M)
Operating Margin-8659.6%-9798.2%-1627.6%-1743.0%-363.0%
Interest Income332K1.74M7.95M26.73M28.65M
Interest Expense00000
Other Income / Expenses90K1.5M7.75M26.8M(341K)
Income Before Tax(1.27B)(5.44B)(1.51B)(2.16B)(534.5M)
Pre-Tax Margin-8659.0%-9795.5%-1619.3%-1721.7%-363.2%
Income Tax Expense(17.48M)(42.29M)(41.95M)(135.36M)(126.15M)
Net Income(1.25B)(5.4B)(1.47B)(2.03B)(408.35M)
Net Margin-8539.4%-9719.3%-1574.2%-1613.9%-277.5%
EPS (Basic)(40.18)(173.87)(47.20)(63.54)(11.11)
EPS (Diluted)(40.18)(173.87)(47.20)(63.54)(11.11)
Weighted Avg Shares31.05M31.05M31.05M31.9M36.75M
Weighted Avg Shares (Diluted)31.05M31.05M31.05M31.9M36.75M

GRAIL, Inc.

NASDAQ:GRAL

Intrinsic Alpha fair value

Locked

Current Price

$102.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.